# T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma

> **NCT02062359** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 2 (actual)

## Conditions studied

- Metastatic Cancer
- Metastatic Melanoma

## Interventions

- **BIOLOGICAL:** Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells
- **DRUG:** Aldesleukin
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT02062359
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-02
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study was closed due to poor accrual.
- **Last updated:** 2016-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02062359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02062359, "T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02062359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*